论文部分内容阅读
国外文献证实,91％的冠心病患者存在舒张功能不全,它与心肌缺血及钙负荷过重关系密切。钙通道阻滞剂通过改变心肌缺血及干扰心肌细胞的钙流动从而可能改善舒张功能。尼卡地平为一新型的双氢吡啶类钙通道阻滞剂,它对心脏舒张功能的影响国内报道不多。我们应用彩色多普勒超声心动图检查证实了口服尼卡地平对冠心病左室舒张功能有理想的改善,现报道如下。1 资料与方法共收集28例冠心病患者,均为心绞痛型及心肌梗塞型(急性心肌梗塞后至少6个月),其中心绞痛型19例,心肌梗塞型9例,
Foreign literature confirmed that 91% of patients with coronary heart disease have diastolic dysfunction, which is closely related to myocardial ischemia and calcium overload. Calcium channel blockers may improve diastolic function by altering myocardial ischemia and interfering with calcium flow in cardiomyocytes. Nicardipine is a new type of dihydropyridine calcium channel blocker, which has little effect on the diastolic function reported in the country. We use color Doppler echocardiography confirmed that oral nicardipine on coronary heart disease with left ventricular diastolic ideal improvement, are reported below. 1 Materials and Methods A total of 28 patients with coronary heart disease were collected, angina type and myocardial infarction type (at least 6 months after acute myocardial infarction), including angina type 19 cases, 9 cases of myocardial infarction,